March 2025 in “MINAR International Journal of Applied Sciences and Technology” Certain genes can predict how well breast cancer patients respond to chemotherapy.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
2 citations
,
December 2012 in “The Professional Medical Journal” Biobran MGN-3 reduces chemotherapy side effects and improves quality of life for breast cancer patients.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
July 2021 in “Plastic and reconstructive surgery. Global open” Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
2 citations
,
June 2005 in “Clinical Oncology” A man's bald spot grew hair after starting cancer treatment with gefitinib.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
24 citations
,
May 2006 in “Proceedings of the National Academy of Sciences of the United States of America” Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.
70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
87 citations
,
January 1996 in “Journal of cellular biochemistry” Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
20 citations
,
March 2021 in “Cancers” Certain genetic variants increase the risk of aggressive prostate cancer.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia” September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” Cancer prevention has advanced significantly, with some strategies proving successful.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
6 citations
,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.